admin

Vasodilator Pharmacology: Nitrates, Hydralazine, Minoxidil and Clinical Safety

Pharmacology education review. Updated 10 November 2026. This is not an individual prescribing protocol; follow current local guidelines and product labeling. Overview Vasodilators reduce vascular smooth-muscle tone through multiple molecular targets. Their effects on venous capacitance, systemic arterial resistance and pulmonary vascular resistance differ, making a drug appropriate for one condition but harmful in another….

Read Full News

Beta Blockers in Cardiovascular Disease: Receptor Selectivity, HFrEF Evidence and Safety

Pharmacology education review. Updated 10 November 2026. This is not an individual prescribing protocol; follow current local guidelines and product labeling. Overview Beta-adrenoceptor antagonists reduce catecholamine effects on cardiac rate, contractility, conduction and renin release. Benefits vary by indication and individual agent: beta blockade is not uniformly proven to reduce mortality in every patient with…

Read Full News

Calcium Channel Blockers: Dihydropyridines, Verapamil, Diltiazem and Safety

Pharmacology education review. Updated 10 November 2026. This is not an individual prescribing protocol; follow current local guidelines and product labeling. Overview Calcium channel blockers (CCBs) inhibit L-type voltage-gated calcium channels and are used for hypertension, chronic angina and selected arrhythmias. Tissue selectivity distinguishes predominantly vascular dihydropyridines from non-dihydropyridines with substantial cardiac conduction effects [1,2]….

Read Full News

Angiotensin Receptor Blockers (ARBs): Mechanism, Renal Protection and Precautions

Pharmacology education review. Updated 10 November 2026. This is not an individual prescribing protocol; follow current local guidelines and product labeling. Overview Angiotensin II receptor blockers (ARBs) inhibit AT1-receptor signaling, lowering vasoconstriction, aldosterone release and sodium retention. They are used for hypertension, albuminuric chronic kidney disease (CKD) and selected heart-failure or post-infarction indications. Clinical benefits…

Read Full News

ACE Inhibitors: Clinical Pharmacology, CKD Benefits, Monitoring and Contraindications

Pharmacology education review. Updated 10 November 2026. This is not an individual prescribing protocol; follow current local guidelines and product labeling. Overview Angiotensin-converting enzyme (ACE) inhibitors decrease formation of angiotensin II and increase bradykinin, promoting vasodilation and reducing aldosterone secretion. Indications include hypertension, selected heart-failure regimens, post-MI LV dysfunction and albuminuric CKD. Medication choice should…

Read Full News

RAAS Modulators: ACE Inhibitors, ARBs, Renin Inhibitors and Mineralocorticoid Antagonists

Educational pharmacology review updated 10 November 2026. This material does not replace clinical evaluation, local licensing rules or patient-specific prescribing guidance. Clinical overview The renin–angiotensin–aldosterone system (RAAS) maintains blood pressure, extracellular volume and potassium homeostasis. Pharmacologic blockade is central to treatment of hypertension, heart failure and albuminuric chronic kidney disease (CKD). These drug families act…

Read Full News

Diuretics: Nephron Sites, Mechanisms, Clinical Uses and Electrolyte Safety

Educational pharmacology review updated 10 November 2026. This material does not replace clinical evaluation, local licensing rules or patient-specific prescribing guidance. Overview Diuretics increase urinary sodium and/or water elimination through distinct nephron targets. They are used to treat volume overload, hypertension and selected electrolyte or endocrine disorders. Their pharmacologic effectiveness and toxicity depend on kidney…

Read Full News

Drugs of Misuse and Substance Use Disorders: Mechanisms, Overdose and Evidence-Based Treatment

Educational pharmacology review updated 10 November 2026. This material does not replace clinical evaluation, local licensing rules or patient-specific prescribing guidance. Overview Psychoactive substances can produce intoxication, tolerance, withdrawal and substance use disorders. Diagnosis considers impaired control, continued use despite harm and other clinical criteria—not exposure or physical dependence alone. Person-centred, non-stigmatizing language and timely…

Read Full News

CNS Stimulants and Nootropics: ADHD Pharmacotherapy, Wakefulness Agents and Safety

Educational pharmacology review updated 10 November 2026. This material does not replace clinical evaluation, local licensing rules or patient-specific prescribing guidance. Overview Central nervous system stimulants have established clinical uses, notably attention-deficit/hyperactivity disorder (ADHD) and selected sleep-wake disorders. The popular term ‘nootropic’ is not a single pharmacological or regulatory class, and claims of meaningful cognition…

Read Full News

Alzheimer Disease Drugs: Cholinesterase Inhibitors, Memantine and Anti-Amyloid Therapy in 2026

Educational pharmacology review updated 10 November 2026. This material does not replace clinical evaluation, local licensing rules or patient-specific prescribing guidance. Overview Alzheimer disease (AD) is a progressive neurodegenerative illness associated with amyloid-β pathology, tau changes and loss of neuronal networks. Drug treatment includes symptomatic cognitive therapies and, for carefully selected patients with early symptomatic,…

Read Full News